Sweden researchers report that have found that nicotine appears to effectively reduce the accumulation of amyloid beta peptide in the brain, suggesting that nicotine treatment may be a novel protective therapy in Alzheimer's disease.

Researchers at the Karolinska Institute, which conducted the study on transgenic mice, said it observed a highly significant 80 percent plaque reduction in the brains of mice treated with nicotine compared to those treated with sugar water.

"Inhibition of beta amyloid accumulation may be essential for effective therapy in Alzheimer's disease," said Dr. David Summers, Chairman and CEO of the biotechnology company Endovasc Ltd..

"We think the same mechanism of action ameliorates Alzheimer's that works on other diseases treated by Angiogenix™," Summers said. Endovasc holds worldwide rights to Angiogenix.

Other Sources: Endovasc